STAAR Surgical (NASDAQ:STAA – Get Free Report) posted its quarterly earnings results on Wednesday. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.06), FiscalAI reports. The company had revenue of $93.53 million during the quarter, compared to analysts’ expectations of $90.60 million. STAAR Surgical had a positive return on equity of 3.31% and a negative net margin of 7.24%.
Here are the key takeaways from STAAR Surgical’s conference call:
- Record first-half performance: Second-quarter revenue rose 111% year over year to $93.5 million, supported by sequential growth in China and double-digit growth across the Americas and EMEA excluding the Middle East.
- Profitability and cash flow improved materially. Net income reached $8.1 million versus a $16.8 million loss a year earlier, adjusted EBITDA was $20 million, and cash increased to $181.5 million with no debt; management expects to end 2026 with more than $200 million in cash.
- EVO+ is gaining traction in China and driving market-share gains. China revenue grew 10% sequentially to $52.3 million, EVO+ represented nearly one-third of units exiting the quarter, and the product commanded a premium without apparent customer resistance, although supply remains constrained.
- Near-term comparisons and operating headwinds remain significant. Third-quarter 2025 included a nonrecurring $25.9 million order, China is expected to be seasonally lower than the second quarter, and tariffs on U.S.-manufactured products will pressure margins until shipments to China are fully produced in Switzerland, targeted by the end of 2026.
- STAAR is broadening its innovation strategy beyond EVO. The company is preparing for first-in-human studies of next-generation products and plans to hire a chief technology officer to develop a broader, Collamer-centered ophthalmology platform.
STAAR Surgical Stock Performance
Shares of NASDAQ STAA traded up $0.47 during trading on Wednesday, reaching $25.41. 1,334,390 shares of the company traded hands, compared to its average volume of 1,188,711. The firm has a 50 day simple moving average of $27.03 and a 200-day simple moving average of $24.04. The company has a quick ratio of 4.31, a current ratio of 5.12 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $1.27 billion, a PE ratio of -59.09 and a beta of 1.26. STAAR Surgical has a 52-week low of $15.59 and a 52-week high of $35.87.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on STAAR Surgical
Institutional Investors Weigh In On STAAR Surgical
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. boosted its position in STAAR Surgical by 0.6% during the 3rd quarter. Invesco Ltd. now owns 150,896 shares of the medical instruments supplier’s stock valued at $4,055,000 after acquiring an additional 956 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of STAAR Surgical by 2,605.1% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 1,016 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of STAAR Surgical by 2.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 52,535 shares of the medical instruments supplier’s stock worth $1,214,000 after acquiring an additional 1,234 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of STAAR Surgical by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock worth $518,000 after acquiring an additional 1,267 shares in the last quarter. Finally, Deutsche Bank AG lifted its position in STAAR Surgical by 3.7% during the fourth quarter. Deutsche Bank AG now owns 38,586 shares of the medical instruments supplier’s stock valued at $891,000 after acquiring an additional 1,382 shares during the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.
STAAR Surgical Company Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.
Featured Stories
- Five stocks we like better than STAAR Surgical
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
